
Brain-Computer Interface Technology Researcher
In 2026, the brain-computer interface industry is entering a critical window period for large-scale application – with continuous policy support, unwavering capital inflow, and accelerated progress driven by the collaborative efforts of the entire industrial chain. Under the strong guidance of national strategy, China's brain-computer interface industry ecosystem is becoming increasingly mature, steadily crossing the tipping point of technological breakthroughs and moving toward a new phase of industrial-scale growth. The exploration and practice of commercialization have become the core engine driving high-quality development in the industry!
To accurately capture the pulse of industry development and identify high-growth potential commercial targets, VCBeat has built upon its earlier in-depth research findings. It continues to apply a "technological breakthrough-clinical progress-commercial potential"三位一体 (trinity) evaluation system for assessing the commercial potential of brain-computer interface (BCI) technologies. This system provides scientific and comprehensive criteria for evaluating the commercial potential of non-invasive BCI products. The three elements are organically linked, progressively layered, offering an end-to-end, professional reference for stakeholders across the industry to assess the commercial feasibility and growth potential of non-invasive BCI products.

Following the heavyweight release of the "List of Invasive Brain-Computer Interface Products with the Most Commercial Potential," VCBeat has further expanded its research scope to include nearly 50 non-invasive brain-computer interface products.A multi-dimensional quantitative evaluation was conducted, and differentiated weights were set according to the characteristics of different tracks. Taking non-invasive brain-computer interfaces as an example, VBInsight assigned the highest priority to "technological innovation" and "clinical application" (each accounting for 30%), with "commercial potential" weighted at 40%. Special note:This assessment focuses on the analysis of the "single product" dimension, aiming to objectively reflect the comprehensive strength of a specific product. The evaluation results do not represent the conditions of other product lines or the overall comprehensive strength of the enterprise (ranked alphabetically by the initial letter of the company name).。

This list, along with the previously released invasive brain-computer interface list, is derived from the "2026 Brain-Computer Interface Early Commercialization Exploration Report." The report was jointly initiated by VBInsight and the Brain-Computer Interface Community. Through in-depth research and interviews with nearly twenty innovative companies in the brain-computer interface field and leading investment institutions, the core of the study revolves around three key questions, seeking answers:
Why:Is Now a Good Time to Explore the Commercialization of Brain-Computer Interfaces?
What is:What are the potential commercialization paths of different technical routes and the core variables for route selection?
How to do it:Crack the Bottleneck, Accelerate Commercialization
Among them, the core viewpoints of non-invasive brain-computer interfaces are as follows:

The full report will be重磅 released at the sub-forum "Brain-Computer Interface Industry Innovation and Investment Forum" of the 2026 Future Healthcare and Pharmaceutical Top 100 Conference, to be held in Shanghai on the morning of May 20!
The 2026 Future Healthcare and Pharmaceutical Top 100 Conference, hosted by VCBeat, features four Brain-Computer Interface (BCI) themed forums. Nearly a hundred prominent guests will share insights on-site, exploring the key questions of "How to develop, invest in, and implement BCIs." Secure your spot at the conference to unlock the core secrets of BCI commercialization, seize the opportunity in this booming industry, and join the golden future of the Brain-Computer Interface sector!
Registration link:https://www.vbdata.cn/1519072168